+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update

  • ID: 3742636
  • Report
  • May 2016
  • Region: Global, Global
  • 56 Pages
  • La Merie Publishing
1 of 2
This Competitive Intelligence report about Biosimilar and Biosuperior Anti-EGF-R Antibodies updates the competitive landscape of biosimilar and biosuperior therapeutic antibodies targeting epithelial growth factor receptor (EGF-R) in comparison with originator anti-EGF-R antibodies to treat solid tumors as of May 2016.

Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently active projects in development of EGF-R targeting antibodies for treatment of solid tumors. In addition, the report lists company-specific R&D pipelines of EGF-R antibodies.

Competitor projects are listed in a tabular format providing information on:

- Drug Codes,
- Target/Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Note: Product cover images may vary from those shown
2 of 2
1. Sales of Anti-EGF-R Antibodies

2. Originator Anti-EGF-R Antibodies
- Erbitux Approved Indications & Pipeline
- Vectibix Approved Indications & Pipeline
- Nimotuzumab Approved Indications & Pipeline
- Portrazza Approved Indications & Pipeline

3. Biosuperior Anti-EGF-R Antibodies
- 3rd Generation Anti-EGF-R Antibodies
- Bispecific Anti-EGF-R Antibodies
- Anti-EGF-R Antibody Drug Conjugates

4. Biosimilar Anti-EGF-R Antibodies
- Erbitux Biosimilar Antibodies:
- Developments in Regulated Markets
- Developments in Less Regulated Markets

5. Corporate Anti-EGF-R Biosimilar & Biosuperior Antibody Pipelines
Note: Product cover images may vary from those shown
3 of 2